70
Participants
Start Date
May 31, 2013
Primary Completion Date
May 31, 2015
Study Completion Date
May 31, 2015
LDE225
LDE225 will be supplied as 200 mg capsules by Novartis. Patients will receive study treatment on an outpatient basis. LDE225 will be dispensed every two weeks for the first four weeks and at the start of every four weeks thereafter, as needed.
Novartis Investigative Site, Vienna
Novartis Investigative Site, Leuven
Novartis Investigative Site, Prahran
Novartis Investigative Site, Debrecen
Novartis Investigative Site, Adelaide
Novartis Investigative Site, Salzburg
Novartis Investigative Site, Yvoir
Novartis Investigative Site, Trondheim
Duke University Medical Center SC-5, Durham
Novartis Investigative Site, Salamanca
Novartis Investigative Site, Magdeburg
Novartis Investigative Site, Valencia
Novartis Investigative Site, Frankfurt
Novartis Investigative Site, Ulm
Novartis Investigative Site, Montreal
Novartis Investigative Site, Montreal
Novartis Investigative Site, Dresden
Novartis Investigative Site, Amsterdam
Novartis Investigative Site, Nijmegen
Novartis Investigative Site, Rotterdam
Novartis Investigative Site, Rotterdam
Novartis Investigative Site, Bergen
Novartis Investigative Site, London
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY